Vongpatanasin Wanpen, Thomas Gail D, Schwartz Randall, Cassis Lisa A, Osborne-Lawrence Sherri, Hahner Lisa, Gibson Linda L, Black Steven, Samols David, Shaul Philip W
Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA.
Circulation. 2007 Feb 27;115(8):1020-8. doi: 10.1161/CIRCULATIONAHA.106.664854. Epub 2007 Feb 5.
Chronic elevations in circulating C-reactive protein (CRP) are associated with a greater risk of hypertension. Whether elevations in CRP cause hypertension is unknown.
Chronic, conscious blood pressure (BP) measurements were performed by radiotelemetry in wild-type CF1 control and CF1 transgenic mice expressing rabbit CRP (CF1-CRP) under the regulation of the phosphoenolpyruvate carboxykinase promoter. Compared with controls, CF1-CRP mice had hypertension that was predominantly systolic, and the severity of hypertension varied in parallel with changes in CRP levels modulated by dietary manipulation. Mice that were hemizygous for the transgene with CRP levels of 9 microg/mL were also hypertensive, indicating that modest elevations in CRP are sufficient to alter BP. CRP transgenic mice had exaggerated BP elevation in response to angiotensin II and a reduction in vascular angiotensin receptor subtype 2 (AT2) expression. In contrast, the decline in BP with angiotensin receptor subtype 1 (AT1) antagonism and vascular AT1 abundance were unaltered, which indicates a selective effect of CRP on AT2. Ex vivo experiments further showed that the CRP-induced decrease in AT2 is a direct effect on the vascular wall, not requiring systemic responses, and that it is reversed by an NO donor, which indicates a role for NO deficiency in the process. In parallel, the chronic inhibition of NO synthase in wild-type mice attenuated vascular AT2 expression without affecting AT1.
These findings provide direct evidence for CRP-induced hypertension, and they further identify a novel underlying mechanism involving downregulation of AT2 related to NO deficiency.
循环中C反应蛋白(CRP)的长期升高与高血压风险增加相关。CRP升高是否导致高血压尚不清楚。
通过无线电遥测技术对野生型CF1对照小鼠和在磷酸烯醇丙酮酸羧激酶启动子调控下表达兔CRP的CF1转基因小鼠(CF1-CRP)进行清醒状态下的慢性血压测量。与对照组相比,CF1-CRP小鼠患有以收缩压升高为主的高血压,且高血压的严重程度随饮食调控引起的CRP水平变化而平行变化。转基因半合子且CRP水平为9微克/毫升的小鼠也患有高血压,这表明CRP的适度升高足以改变血压。CRP转基因小鼠对血管紧张素II的血压升高反应增强,血管紧张素受体2型(AT2)表达降低。相反,血管紧张素受体1型(AT1)拮抗作用导致的血压下降以及血管AT1丰度未发生改变,这表明CRP对AT2有选择性作用。体外实验进一步表明,CRP诱导的AT2降低是对血管壁的直接作用,不需要全身反应,并且可被一氧化氮(NO)供体逆转,这表明NO缺乏在该过程中起作用。同时,野生型小鼠中NO合酶的慢性抑制减弱了血管AT2表达,而不影响AT1。
这些发现为CRP诱导的高血压提供了直接证据,并进一步确定了一种新的潜在机制,即与NO缺乏相关的AT2下调。